BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AdvanDx, Inc. Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Candida Bloodstream Pathogens


3/31/2010 6:54:09 AM

WOBURN, Mass. and VEDBAEK, Denmark, March 31 /PRNewswire/ -- AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its C. albicans PNA FISH® and C. albicans/C. glabrata PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes. Clinical validation studies performed at hospitals in the United States demonstrated 100% agreement between the 90 minutes protocol, the original PNA FISH protocol and conventional identification methods, ensuring the faster protocol maintains the very high sensitivity and specificity required versus slower, conventional methods.

Candidemia, a bloodstream infection caused by Candida species, is one of the most serious hospital acquired infections, afflicting over 24,000 patients in the U.S. every year. Immunocompromised transplantation, oncology and AIDS patients are especially at risk for contracting the infection with mortality rates as high as 50%.(1) While identification of the infecting Candida species is used to guide effective antifungal therapy, conventional laboratory identification methods can take up to 5 days or longer.(2) Therefore, patients are often treated empirically either with fluconazole, a relatively inexpensive, generic antifungal agent, or with an echinocandin, a new class of antifungal drugs that have broad activity against Candida species but are also substantially more expensive. As a result, patients often receive inappropriate, inadequate or sometimes unnecessarily broad therapy.

PNA FISH is the only FDA cleared method that provides rapid, molecular identification of Candida species direct from positive blood cultures. Results are available in hours instead of days, and enable clinicians to optimize antifungal drug selection much earlier for patients with candidemia. A study performed at the University of Maryland Medical Center demonstrated that PNA FISH improved time to species identification by 35 to 52 hours. The faster results enabled clinicians to provide optimal antifungal therapy earlier and helped reduce antifungal costs by $1,800 per patient, all without adversely affecting patient outcomes.(3) In a separate study, Della-Latta et al. at Columbia University Medical Center demonstrated that rapid PNA FISH results led to an early switch to caspofungin, an echinocandin, for 81% of patients with C. glabrata infections treated empirically with fluconazole. The rapid results also led to an early switch to fluconazole for 70% of patients with C. albicans infections treated empirically with caspofungin. Based on the study results, the authors concluded that the PNA FISH test "can impact the appropriate selection of the most effective antifungal therapy, thereby making it a clinically relevant diagnostic assay."(4)

With the introduction of the 90 minutes PNA FISH protocol, laboratories will be able to further improve turn-around times for critical results and thereby help clinicians further improve antifungal selection, care, and outcomes for patients with candidemia.

"The FDA clearances for both C. albicans PNA FISH and C. albicans/C. glabrata PNA FISH marks a major milestone for AdvanDx as it completes our transition to the 90 minute protocol for PNA FISH tests covering all four Gram-stain classes," said Thais T. Johansen, President and CEO of AdvanDx. "Hospitals can now provide accurate, actionable species identification results for the majority of critical bloodstream pathogens in just 90 minutes, enabling clinicians to improve antimicrobial therapy and outcomes for their patients," Johansen concluded.

About AdvanDx

AdvanDx is the leading provider of advanced molecular diagnostic products for the diagnosis and treatment of life-threatening, bloodstream infections. AdvanDx's easy-to-use products provide fast and accurate results that enable dramatic improvements in patient care and help to save lives and reduce hospital costs.

AdvanDx's products employ standard laboratory techniques and equipment to reduce startup, implementation, technician and maintenance time, while providing fast results without sacrificing accuracy. Major medical centers, reference labs, government institutions and community hospitals throughout the United States, Europe and Asia rely on AdvanDx products as integral parts of their medical care.

For more information visit www.AdvanDx.com

C. albicans PNA FISH® and C. albicans/C. glabrata PNA FISH® are distributed by bioMerieux, Inc. in the United States.

References:

(1) Spellberg et al. Clin. Infec. Dis. 42: 244-251. 2005

(2) Fridkin et al. 2005 Nov 15;41(10):1455-60

(3) Forrest et al. J. Clin. Microbiol. 2006 44: 3381-338

(4) Della-Latta et al. Impact of Rapid Identification of C. albicans and C. glabrata Directly from Blood Cultures using PNA FISH Technology on Selection of Antifungal Therapy. Poster 1382. ECCMID 2008. Barcelona, Spain.

PN1742A

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES